Daniel J Jackson1, Leonard B Bacharier1, David T Mauger1, Susan Boehmer1, Avraham Beigelman1, James F Chmiel1, Anne M Fitzpatrick1, Jonathan M Gaffin1, Wayne J Morgan1, Stephen P Peters1, Wanda Phipatanakul1, William J Sheehan1, Michael D Cabana1, Fernando Holguin1, Fernando D Martinez1, Jacqueline A Pongracic1, Sachin N Baxi1, Mindy Benson1, Kathryn Blake1, Ronina Covar1, Deborah A Gentile1, Elliot Israel1, Jerry A Krishnan1, Harsha V Kumar1, Jason E Lang1, Stephen C Lazarus1, John J Lima1, Dayna Long1, Ngoc Ly1, Jyothi Marbin1, James N Moy1, Ross E Myers1, J Tod Olin1, Hengameh H Raissy1, Rachel G Robison1, Kristie Ross1, Christine A Sorkness1, Robert F Lemanske1. 1. From the Department of Pediatrics, University of Wisconsin School of Medicine and Public Health (D.J.J., R.F.L.J.), and the University of Wisconsin-Madison (C.A.S.) - both in Madison; the Department of Pediatrics, Washington University in St. Louis School of Medicine and St. Louis Children's Hospital, St. Louis (L.B.B., A.B.); the Department of Public Health Sciences, Penn State University, Hershey (D.T.M., S.B.), and the University of Pittsburgh Asthma Institute at University of Pittsburgh Medical Center-University of Pittsburgh School of Medicine (F.H.) and the Department of Pediatrics, Allegheny General Hospital (D.A.G.), Pittsburgh - all in Pennsylvania; the Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children's Hospital, Cleveland (J.F.C., R.E.M., K.R.); the Department of Pediatrics, Emory University, Atlanta (A.M.F.); the Divisions of Respiratory Diseases (J.M.G.) and Allergy-Immunology, Boston Children's Hospital (W.P., W.J.S., S.N.B.), Harvard Medical School, and Brigham and Women's Hospital, Harvard Medical School (E.I.) - all in Boston; the Arizona Respiratory Center, University of Arizona, Tucson (W.J.M., F.D.M.); Wake Forest University School of Medicine, Winston-Salem, NC (S.P.P.); the Departments of Pediatrics (M.D.C., N.L.), Epidemiology (M.D.C.), Biostatistics (M.D.C.), and Medicine (S.C.L.), University of California, San Francisco (UCSF), and UCSF Benioff Children's Hospital (M.D.C.) - both in San Francisco; Ann and Robert H. Lurie Children's Hospital of Chicago (J.A.P., R.G.R.), University of Illinois at Chicago (J.A.K., H.V.K.), and the Department of Pediatrics, Stroger Hospital of Cook County, Rush University Medical Center (J.N.M.) - all in Chicago; UCSF Benioff Children's Hospital Oakland, Oakland (M.B., D.L., J.M.); Nemours Children's Health System, Jacksonville (K.B., J.J.L.), and Nemours Children's Hospital, University of Central Florida College of Medicine, Orlando (J.E.L.) - both in Florida; the Department of Pediatrics, National Jewish Health, Denver (R.C., J.T.O.); and the Department of Pediatrics, University of New Mexico, Albuquerque (H.H.R.).
Abstract
BACKGROUND: Asthma exacerbations occur frequently despite the regular use of asthma-controller therapies, such as inhaled glucocorticoids. Clinicians commonly increase the doses of inhaled glucocorticoids at early signs of loss of asthma control. However, data on the safety and efficacy of this strategy in children are limited. METHODS: We studied 254 children, 5 to 11 years of age, who had mild-to-moderate persistent asthma and had had at least one asthma exacerbation treated with systemic glucocorticoids in the previous year. Children were treated for 48 weeks with maintenance low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) and were randomly assigned to either continue the same dose (low-dose group) or use a quintupled dose (high-dose group; fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at the early signs of loss of asthma control ("yellow zone"). Treatment was provided in a double-blind fashion. The primary outcome was the rate of severe asthma exacerbations treated with systemic glucocorticoids. RESULTS: The rate of severe asthma exacerbations treated with systemic glucocorticoids did not differ significantly between groups (0.48 exacerbations per year in the high-dose group and 0.37 exacerbations per year in the low-dose group; relative rate, 1.3; 95% confidence interval, 0.8 to 2.1; P=0.30). The time to the first exacerbation, the rate of treatment failure, symptom scores, and albuterol use during yellow-zone episodes did not differ significantly between groups. The total glucocorticoid exposure was 16% higher in the high-dose group than in the low-dose group. The difference in linear growth between the high-dose group and the low-dose group was -0.23 cm per year (P=0.06). CONCLUSIONS: In children with mild-to-moderate persistent asthma treated withdaily inhaled glucocorticoids, quintupling the dose at the early signs of loss of asthma control did not reduce the rate of severe asthma exacerbations or improve other asthma outcomes and may be associated with diminished linear growth. (Funded by the National Heart, Lung, and Blood Institute; STICS ClinicalTrials.gov number, NCT02066129 .).
RCT Entities:
BACKGROUND:Asthma exacerbations occur frequently despite the regular use of asthma-controller therapies, such as inhaled glucocorticoids. Clinicians commonly increase the doses of inhaled glucocorticoids at early signs of loss of asthma control. However, data on the safety and efficacy of this strategy in children are limited. METHODS: We studied 254 children, 5 to 11 years of age, who had mild-to-moderate persistent asthma and had had at least one asthma exacerbation treated with systemic glucocorticoids in the previous year. Children were treated for 48 weeks with maintenance low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) and were randomly assigned to either continue the same dose (low-dose group) or use a quintupled dose (high-dose group; fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at the early signs of loss of asthma control ("yellow zone"). Treatment was provided in a double-blind fashion. The primary outcome was the rate of severe asthma exacerbations treated with systemic glucocorticoids. RESULTS: The rate of severe asthma exacerbations treated with systemic glucocorticoids did not differ significantly between groups (0.48 exacerbations per year in the high-dose group and 0.37 exacerbations per year in the low-dose group; relative rate, 1.3; 95% confidence interval, 0.8 to 2.1; P=0.30). The time to the first exacerbation, the rate of treatment failure, symptom scores, and albuterol use during yellow-zone episodes did not differ significantly between groups. The total glucocorticoid exposure was 16% higher in the high-dose group than in the low-dose group. The difference in linear growth between the high-dose group and the low-dose group was -0.23 cm per year (P=0.06). CONCLUSIONS: In children with mild-to-moderate persistent asthma treated with daily inhaled glucocorticoids, quintupling the dose at the early signs of loss of asthma control did not reduce the rate of severe asthma exacerbations or improve other asthma outcomes and may be associated with diminished linear growth. (Funded by the National Heart, Lung, and Blood Institute; STICS ClinicalTrials.gov number, NCT02066129 .).
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Chitra Dinakar; John Oppenheimer; Jay Portnoy; Leonard B Bacharier; James Li; Carolyn M Kercsmar; David Bernstein; Joann Blessing-Moore; David Khan; David Lang; Richard Nicklas; Christopher Randolph; Diane Schuller; Sheldon Spector; Stephen A Tilles; Dana Wallace Journal: Ann Allergy Asthma Immunol Date: 2014-08 Impact factor: 6.347
Authors: Lara J Akinbami; Jeanne E Moorman; Cathy Bailey; Hatice S Zahran; Michele King; Carol A Johnson; Xiang Liu Journal: NCHS Data Brief Date: 2012-05
Authors: Amy L O'Brian; Robert F Lemanske; Michael D Evans; Ronald E Gangnon; James E Gern; Daniel J Jackson Journal: J Allergy Clin Immunol Date: 2012-01-10 Impact factor: 10.793
Authors: Hans Bisgaard; Pascal Le Roux; Ditlef Bjåmer; Andrzej Dymek; Jan H Vermeulen; Christer Hultquist Journal: Chest Date: 2006-12 Impact factor: 9.410
Authors: Janet Oborne; Kevin Mortimer; Richard B Hubbard; Anne E Tattersfield; Tim W Harrison Journal: Am J Respir Crit Care Med Date: 2009-07-09 Impact factor: 21.405
Authors: Sandra Voorend-van Bergen; Anja A Vaessen-Verberne; Anneke M Landstra; Hein J Brackel; Norbert J van den Berg; Daan Caudri; Johan C de Jongste; Peter J Merkus; Mariëlle W Pijnenburg Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: Francine M Ducharme; Chantal Lemire; Francisco J D Noya; G Michael Davis; Nathalie Alos; Hélène Leblond; Cheryl Savdie; Jean-Paul Collet; Lyudmyla Khomenko; Georges Rivard; Robert W Platt Journal: N Engl J Med Date: 2009-01-22 Impact factor: 91.245
Authors: Michael E Wechsler; Stanley J Szefler; Victor E Ortega; Jacqueline A Pongracic; Vernon Chinchilli; John J Lima; Jerry A Krishnan; Susan J Kunselman; David Mauger; Eugene R Bleecker; Leonard B Bacharier; Avraham Beigelman; Mindy Benson; Kathryn V Blake; Michael D Cabana; Juan-Carlos Cardet; Mario Castro; James F Chmiel; Ronina Covar; Loren Denlinger; Emily DiMango; Anne M Fitzpatrick; Deborah Gentile; Nicole Grossman; Fernando Holguin; Daniel J Jackson; Harsha Kumar; Monica Kraft; Craig F LaForce; Jason Lang; Stephen C Lazarus; Robert F Lemanske; Dayna Long; Njira Lugogo; Fernando Martinez; Deborah A Meyers; Wendy C Moore; James Moy; Edward Naureckas; J Tod Olin; Stephen P Peters; Wanda Phipatanakul; Loretta Que; Hengameh Raissy; Rachel G Robison; Kristie Ross; William Sheehan; Lewis J Smith; Julian Solway; Christine A Sorkness; Lisa Sullivan-Vedder; Sally Wenzel; Steven White; Elliot Israel Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: Danielle Perry; Samantha Moe; Christina Korownyk; Adrienne J Lindblad; Michael R Kolber; Betsy Thomas; Joey Ton; Scott Garrison; G Michael Allan Journal: Can Fam Physician Date: 2019-04 Impact factor: 3.275
Authors: Danielle Perry; Samantha Moe; Christina Korownyk; Adrienne J Lindblad; Michael R Kolber; Betsy Thomas; Joey Ton; Scott Garrison; G Michael Allan Journal: Can Fam Physician Date: 2019-04 Impact factor: 3.275
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2019 Jan-Mar Impact factor: 2.219
Authors: Stephen C Lazarus; Jerry A Krishnan; Tonya S King; Jason E Lang; Kathryn V Blake; Ronina Covar; Njira Lugogo; Sally Wenzel; Vernon M Chinchilli; David T Mauger; Anne-Marie Dyer; Homer A Boushey; John V Fahy; Prescott G Woodruff; Leonard B Bacharier; Michael D Cabana; Juan C Cardet; Mario Castro; James Chmiel; Loren Denlinger; Emily DiMango; Anne M Fitzpatrick; Deborah Gentile; Annette Hastie; Fernando Holguin; Elliot Israel; Daniel Jackson; Monica Kraft; Craig LaForce; Robert F Lemanske; Fernando D Martinez; Wendy Moore; Wayne J Morgan; James N Moy; Ross Myers; Stephen P Peters; Wanda Phipatanakul; Jacqueline A Pongracic; Loretta Que; Kristie Ross; Lewis Smith; Stanley J Szefler; Michael E Wechsler; Christine A Sorkness Journal: N Engl J Med Date: 2019-05-19 Impact factor: 91.245
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793
Authors: Anne M Fitzpatrick; Leonard B Bacharier; Daniel J Jackson; Stanley J Szefler; Avraham Beigelman; Michael Cabana; Ronina Covar; Theresa Guilbert; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Wayne Morgan; Wanda Phipatanakul; Jacqueline A Pongracic; Hengameh H Raissy; Robert S Zeiger; David T Mauger Journal: J Allergy Clin Immunol Pract Date: 2020-03-07